Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study

por Boye, Kristina S., Lage, Maureen J., Kiljański, Jacek
Publicado 2021

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review

por Hirose, Takahisa, Chen, Ching-Chu, Ahn, Kyu Jeung, Kiljański, Jacek
Publicado 2019

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100

por Hollander, Priscilla A., Kiljanski, Jacek, Spaepen, Erik, Harris, Cynthia J.
Publicado 2019

Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes

por Perez-Nieves, Magaly, Boye, Kristina S., Kiljanski, Jacek, Cao, Dachung, Lage, Maureen J.
Publicado 2018

Evaluating glucose‐lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial

por Sinclair, Alan J., Heller, Simon R., Pratley, Richard E., Duan, Ran, Heine, Robert J., Festa, Andreas, Kiljański, Jacek
Publicado 2020

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

por Simó, Rafael, Guerci, Bruno, Schernthaner, Guntram, Gallwitz, Baptist, Rosas-Guzmàn, Juan, Dotta, Francesco, Festa, Andreas, Zhou, Ming, Kiljański, Jacek
Publicado 2015

Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM)

por Heller, Simon R., Pratley, Richard E., Sinclair, Alan, Festa, Andreas, Kiljański, Jacek, Brusko, Cynthia S., Duan, Ran, Heine, Robert J.
Publicado 2017

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study

por Matthaei, Stephan, Reaney, Matthew, Mathieu, Chantal, Östenson, Claes-Göran, Krarup, Thure, Guerci, Bruno, Kiljanski, Jacek, Petto, Helmut, Bruhn, David, Theodorakis, Michael
Publicado 2012

Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of...

por Pratley, Richard E., Rosenstock, Julio, Heller, Simon R., Sinclair, Alan, Heine, Robert J., Kiljański, Jacek, Brusko, Cynthia S., Duan, Ran, Festa, Andreas
Publicado 2018

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE

por Mathieu, Chantal, Östenson, Claes-Göran, Matthaei, Stephan, Reaney, Matthew, Krarup, Thure, Guerci, Bruno, Kiljański, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Theodorakis, Michael
Publicado 2013

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study

por Reaney, Matthew, Mathieu, Chantal, Östenson, Claes-Göran, Matthaei, Stephan, Krarup, Thure, Kiljański, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Theodorakis, Michael, Guerci, Bruno
Publicado 2013

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries

por Östenson, Claes-Göran, Matthaei, Stephan, Reaney, Matthew, Krarup, Thure, Guerci, Bruno, Kiljanski, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Bruhn, David, Mathieu, Chantal, Theodorakis, Michael
Publicado 2013

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study

por Kiiskinen, Urpo, Matthaei, Stephan, Reaney, Matthew, Mathieu, Chantal, Östenson, Claes-Göran, Krarup, Thure, Theodorakis, Michael, Kiljański, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Guerci, Bruno
Publicado 2013